Mariachiara Santorsola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariachiara Santorsola has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Ottaiano
Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Via Mariano Semmola, 80131 Naples, Italy
2 shared publications - Francesco Sabbatino
Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy
2 shared publications - Marco Cascella
Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy
2 shared publications - Alessandro Vittori
Department of Anesthesia, Critical Care and Pain Medicine, ARCO, Ospedale Pediatrico Bambino Gesù IRCCS, Piazza S. Onofrio 4, 00165 Rome, Italy
1 shared publication - Anna Crispo
Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, Italy
1 shared publication - Carmine Picone
Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Via Mariano Semmola, 80131 Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 13 May 2026
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 7, 1002371
Oligometastatic versus polymetastatic colon cancer: functional and genomic determinants of divergent metastatic trajectories
Aim: The aim of this study is to investigate the molecular and functional features underlying the clinical heterogeneity between oligometastatic (OM) and polymetastatic (PM) colon cancer. Methods: We performed a genotype-phenotype analysis in a homogeneous cohort of 127 patients with metastatic colon cancer (mCC) profiled using the same next-generation sequencing platform (TruSight Oncology® 500). OM disease was defined as the presence of one to three metastatic lesions per involved organ, involving no more than two organs overall, with all lesions measuring < 70 mm in maximum diameter and no single lesion > 25 mm. Molecular alterations, microsatellite instability (MSI), tumor mutational burden (TMB), and overall survival (OS) were analyzed. Gene Ontology (GO) enrichment and Phenolyzer network analyses were applied to explore functional differences between prognostically distinct molecular subgroups. Results: OM patients showed a striking survival advantage compared with PM patients [median OS not reached versus 29 months; hazard ratio (HR): 0.20, P < 0.0001], validating the clinical distinction between the two phenotypes. PM disease was significantly enriched for RAS mutations, whereas OM disease was associated with MSI-high status and elevated TMB. Canonical driver alterations were largely shared between groups, and Phenolyzer analysis revealed similar core oncogenic networks centered on adenomatous polyposis coli (APC), tumor protein p53 (TP53), and epidermal growth factor receptor (EGFR). In contrast, GO analysis demonstrated selective enrichment in PM tumors for molecular functions related to ATP binding, nucleotide binding, and protein kinase activity, consistent with enhanced bioenergetic demand and signaling intensity. Conclusions: These findings support refined biological stratification of mCC and the exploration of personalized, metastasis-directed strategies, potentially incorporating immunological modulation in OM disease.
- 13 May 2026
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 7, 1002371
Open AccessOligometastatic versus polymetastatic colon cancer: functional and genomic determinants of divergent metastatic trajectories
Aim: The aim of this study is to investigate the molecular and functional features underlying the clinical heterogeneity between oligometastatic (OM) and polymetastatic (PM) colon cancer. Methods: We performed a genotype-phenotype analysis in a homogeneous cohort of 127 patients with metastatic colon cancer (mCC) profiled using the same next-generation sequencing platform (TruSight Oncology® 500). OM disease was defined as the presence of one to three metastatic lesions per involved organ, involving no more than two organs overall, with all lesions measuring < 70 mm in maximum diameter and no single lesion > 25 mm. Molecular alterations, microsatellite instability (MSI), tumor mutational burden (TMB), and overall survival (OS) were analyzed. Gene Ontology (GO) enrichment and Phenolyzer network analyses were applied to explore functional differences between prognostically distinct molecular subgroups. Results: OM patients showed a striking survival advantage compared with PM patients [median OS not reached versus 29 months; hazard ratio (HR): 0.20, P < 0.0001], validating the clinical distinction between the two phenotypes. PM disease was significantly enriched for RAS mutations, whereas OM disease was associated with MSI-high status and elevated TMB. Canonical driver alterations were largely shared between groups, and Phenolyzer analysis revealed similar core oncogenic networks centered on adenomatous polyposis coli (APC), tumor protein p53 (TP53), and epidermal growth factor receptor (EGFR). In contrast, GO analysis demonstrated selective enrichment in PM tumors for molecular functions related to ATP binding, nucleotide binding, and protein kinase activity, consistent with enhanced bioenergetic demand and signaling intensity. Conclusions: These findings support refined biological stratification of mCC and the exploration of personalized, metastasis-directed strategies, potentially incorporating immunological modulation in OM disease.
- Open Access
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , e9211861
Feasibility Assessment of Telehealth‐Based Cancer Pain Management Through Machine Learning: A Prospective Clinical Study
Background: Although telehealth strategies can be effectively adopted to manage cancer pain, identifying the optimal care pathway for tailoring interventions and allocating resources remains difficult. Artificial intelligence and machine learning (ML) may help clinicians develop more accurate strategies for predicting whether patients need remote consultations or in‐person evaluations. Methods: Data from two cohorts of cancer pain patients were analyzed. Variables included sociodemographic and clinical data, including age, sex, ECOG performance status, metastases, bone metastases, pain type, breakthrough cancer pain (BTCP), and rapid onset opioids (ROOs) therapy. The main outcome was the number of televisits (one versus multiple). For preprocessing, datasets from the two cohorts were harmonized by aligning variable definitions, coding schemes, and data formats. Six models were tested: logistic regression, random forest (RF), gradient boosting machine (GBM), support vector machine (SVM), k‐nearest neighbors (KNNs), and multilayer perceptron (MLP). Training and tuning used a 7‐repeated 5‐fold cross‐validation approach. Performance was evaluated on a hold‐out test set using F 1‐score, accuracy, and AUC‐ROC. A sensitivity analysis with two scenarios was performed to verify the effects of class weighting and excluding the cohort variable. Results: The final dataset included 270 patients. No statistically significant associations were identified between the available variables and the number of televisits. F 1‐scores across models ranged from 0.33 (RF) to 0.65 (MLP), accuracy from 0.45 (RF) to 0.55 (SVM), and AUC‐ROC from 0.43 (RF) to 0.65 (LR). DeLong tests showed no significant differences between algorithms ( p > 0.05). Although the MLP achieved the highest F 1‐score, it exhibited instability, with 91% of null F 1‐scores. Incorporating class weights slightly improved SVM ( F 1 = 0.58 and AUC = 0.62) and LR ( F 1 = 0.53 and AUC = 0.63) though not significantly. Conclusion: Although no model demonstrated strong predictive power, this ML‐based framework shows the potential of using structured telemedicine data to model clinical workload and optimize follow‐up strategies in cancer pain care. Trial Registration: ClinicalTrials.gov identifier: NCT04726228 and NCT07038434
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , e9211861
Open AccessFeasibility Assessment of Telehealth‐Based Cancer Pain Management Through Machine Learning: A Prospective Clinical Study
Background: Although telehealth strategies can be effectively adopted to manage cancer pain, identifying the optimal care pathway for tailoring interventions and allocating resources remains difficult. Artificial intelligence and machine learning (ML) may help clinicians develop more accurate strategies for predicting whether patients need remote consultations or in‐person evaluations. Methods: Data from two cohorts of cancer pain patients were analyzed. Variables included sociodemographic and clinical data, including age, sex, ECOG performance status, metastases, bone metastases, pain type, breakthrough cancer pain (BTCP), and rapid onset opioids (ROOs) therapy. The main outcome was the number of televisits (one versus multiple). For preprocessing, datasets from the two cohorts were harmonized by aligning variable definitions, coding schemes, and data formats. Six models were tested: logistic regression, random forest (RF), gradient boosting machine (GBM), support vector machine (SVM), k‐nearest neighbors (KNNs), and multilayer perceptron (MLP). Training and tuning used a 7‐repeated 5‐fold cross‐validation approach. Performance was evaluated on a hold‐out test set using F 1‐score, accuracy, and AUC‐ROC. A sensitivity analysis with two scenarios was performed to verify the effects of class weighting and excluding the cohort variable. Results: The final dataset included 270 patients. No statistically significant associations were identified between the available variables and the number of televisits. F 1‐scores across models ranged from 0.33 (RF) to 0.65 (MLP), accuracy from 0.45 (RF) to 0.55 (SVM), and AUC‐ROC from 0.43 (RF) to 0.65 (LR). DeLong tests showed no significant differences between algorithms ( p > 0.05). Although the MLP achieved the highest F 1‐score, it exhibited instability, with 91% of null F 1‐scores. Incorporating class weights slightly improved SVM ( F 1 = 0.58 and AUC = 0.62) and LR ( F 1 = 0.53 and AUC = 0.63) though not significantly. Conclusion: Although no model demonstrated strong predictive power, this ML‐based framework shows the potential of using structured telemedicine data to model clinical workload and optimize follow‐up strategies in cancer pain care. Trial Registration: ClinicalTrials.gov identifier: NCT04726228 and NCT07038434